Nemera and Therakind partner on DriDose® dry powder intranasal technology

‍Nemera and Therakind have partnered to bring together Nemera’s know-how in combination product device development and industrialisation, with Therakind’s experience in developing and delivering innovative medicines to patients.

The DriDose® platform - a dry powder intranasal device portfolio developed by Therakind - perfectly complements Nemera’s existing range of nasal delivery solutions, which currently supports liquid formulations. Nemera, a global leader in design, development and manufacturing of drug delivery device solutions,  broadens its innovative nasal portfolio to include a complete dry powder delivery platform, further enhancing its end-to-end offering for pharmaceutical and biotechnology partners.

Therakind, a UK-based pharmaceutical company with a strong track record in transitioning products from development to regulatory approval, is consolidating its core business of drug device combination product development. Therakind will continue to leverage the DriDose® platform to enhance patient outcomes both with internal projects and in collaboration with third parties.

Dr Susan Conroy, CEO of Therakind, said:

We are delighted to partner with Nemera, known for its expertise in drug delivery solutions and novel device industrialisation. As a market leader in devices with a global presence, Nemera is an ideal partner for the DriDose® portfolio industrialisation and expansion.

Dimitri Grasswill, Vice President of Nemera’s Ear, Nose and Throat business, added:

We are thrilled to partner with Therakind and benefit from their strong track record in pharmaceutical development and regulatory approvals. The innovative DriDose® technology will open Nemera to new therapeutic areas in nasal drug delivery and will significantly improve patients’ lives - it perfectly complements our product portfolio especially by targeting unmet needs in systemic and non-systemic treatments.” 

Together, Nemera and Therakind will accelerate the development of next generation nasal therapies, offering pharmaceutical partners expanded formulation expertise and innovative, patient friendly devices.